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Chemotherapy often results in the emergence of multidrug
resistance in cancer cells and over-expression of P-glycoprotein
(MDR-1) is widely accepted to be a contributor to the resistance to
some chemotherapeutic reagents. Reversal of multidrug resis-
tance, therefore, is important for the successful treatment of
many tumours following drug treatment. However, clinical trials
utilising inhibitors of MDR-1 have not been that successful,
indicating that unknown mechanisms may also contribute to
MDR-1-mediated resistance. 
Mammalian cells possess the intrinsic capacity to initiate cell
suicide through apoptosis. Three types of stimuli normally initiate
this process: the deprivation of survival factors, signals through
pro-apoptotic receptors or cell-damaging stress (Kinloch et al,
1999). In recent years, it has been demonstrated that chemical
toxicity is accompanied by the induction of a large number of
stress or adaptive response genes (Keyse, 1995). External or
internal stimuli trigger a cascade of intracellular signals leading to
proliferation, differentiation or apoptosis. Some tumour cells may
actually avoid the ‘apoptotic safety-net’ because the damage
signal generated by the antitumour agent fails to activate the
necessary pathways required to initiate apoptosis. Indeed, activa-
tion of the signalling pathways regulating cell survival has been
shown to play an anti-apoptotic role after treatment with various
chemotherapeutic drugs, ionising radiation or oxidant injury (Dent
et al, 1998; Wang et al, 1998; Plo et al, 1999). 
Many signal-transduction pathways have now been described
and well characterised. Of these, the mitogen-activated protein
kinase (MAPK) family has emerged as one of the most important
membrane-to-nucleus signalling mechanisms, functioning as a
mediator of cellular responses to a variety of cellular stimuli
(Hunter, 1997). The MAPK family has been classified into 3
distinct subfamilies: the extracellular signal-regulated protein
kinases (ERKs) including ERK1 and ERK2, the stress-activated 
c-Jun N-terminal protein kinase (JNKs) and p38 kinase. ERKs are
activated by growth factors, cytokines and hormones.
Constitutive activation of this pathway, for example by mutations
in the Ras oncogene, is sufficient to promote cell transformation
(Mansour et al, 1994; Hoshino et al, 1999). In addition, exposure
of cells to antitumour agents such as Taxol can activate the
ERK1/2 MAP kinase (Schulte et al, 1996; Blagosklonny et al,
1999). Cisplatin is also known to activate the JNK pathway in
human ovarian cancer cells (Hayakawa et al, 1999). Inhibitors of
the ERK1/2 MAP kinase cascade such as PD184352 have been
shown to inhibit the growth of human colon cancer xenografts in
mice by as much as 80% (Sebolt-Leopold et al, 1999).
Furthermore, studies have also shown that the activation of the
ERK1/2 MAP kinase pathway plays a critical role in leukaemia
cell survival after treatment with chemotherapeutic drugs and
ionising radiation (Dent et al, 1998). 
In addition to the ERK1/2 MAP kinase cascade, phosphatidyli-
nositol-3-kinase (PI3K) is also an effector of Ras signalling
(Franke et al, 1997; Kauffmann-Zeh et al, 1997). It is assumed that
3′ -phosphoinositides generated by P13K act as second messengers
and can bind to the pleckstrin homology (PH) domain of Akt/PKB,
resulting in a conformational change of the protein. This promotes
Akt/PKB activation through the phosphorylation at residues Thr-
308 and Ser-473 by upstream kinases. Akt/PKB has emerged as a
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et al, 1999). It has recently been shown that approximately 40% 
of ovarian cancers contain increased copy number of the PI3KCA
gene and increased PI3K activity (Shayesteh et al, 1999). The
consequent activation of Akt/PKB is considered to be an important
factor in the progression of ovarian cancer (Yuan et al, 2000).
Recently it has been found that, in certain circumstances, PI3K
plays a role in receptor-driven activation of the ERK1/2 MAP
kinase signalling cascade (Wennstrom and Downward, 1999;
Scheid and Woodgett, 2000). Although the 2 cascades were once
thought to be distinct and act in parallel, induction of PI3K may
actually deliver a co-operative activation signal to the ERK 1/2
MAP kinase pathway. Cross-talk between the 2 cascades may play
a crucial role in the regulation of cell growth and survival. 
The chemotherapeutic agent, Taxol, has been used in the treat-
ment of a wide range of human malignancies including lung, head
and neck, breast and ovarian cancer (Ling et al, 1998). The short-
term survival rate of these cancers has improved. However, the 5-
year survival rate has remained essentially unchanged. The major
limitation to successful treatment is that the initial round of treat-
ment with Taxol does not kill all the tumour cells and invariably
the tumour returns in a manner that is resistant to further drug
treatment. 
On the basis of these observations we were interested in deter-
mining whether these signalling pathways play a role in chemi-
cally induced cell death, and whether they are involved in tumour
cell chemoresistance. To this end we investigated the role of these
pathways in the resistance of ovarian cancer cells to the important
anti-tumour agent Taxol. 
MATERIALS AND METHODS 
Cell lines and cell culture 
Human ovarian cancer cell line A1847 (Eva et al, 1982) was
obtained from the Imperial Cancer Research Fund (Clare Hall,
London). Cells were grown as monolayers in RPMI medium
supplemented with 10% fetal calf serum, (100 U ml–1) penicillin
and (100 µ gm l –1) streptomycin (GIBCOBRL, Paisley, UK) at
37˚C in a 5% CO2 atmosphere. A1847 cells were exposed to
200 ng ml–1 EMS (ethyl methane sulfonate) for 24 hours, allowing
the cells to recover for 48 hours, then treating with 1 nM Taxol.
These cells were allowed to adapt to this concentration of Taxol
for 3 passages before the Taxol concentration was increased to
2.5 nM. This incremental exposure to Taxol was continued until
cells had become resistant to 3 µ M Taxol. After each incremental
change in the Taxol concentration, individual colonies were
isolated with cloning cylinders to generate cell lines which would
grow in the presence of 0.5 µ M (A1847/TX0.5), 1 µ M
(A1847/TX1) and 3 µ M (A1847/TX3) Taxol, respectively. 
Plasmid construction and establishment of the cell
lines expressing MDR-1 by DNA transfection 
Full-length human Mdr-1 cDNA (4.2 kb) was excised from the
plasmid pBluescript/Mdr-1 (Kioka et al, 1989) by BstUI/XhoI
digestion and ligated into the EcoRV/XhoI sites of an expression
vector pcDNA3 (Invitrogen) containing a G418 gene to construct
the plasmid pcDNA/Mdr-1. DNA transfection was carried out as
described previously (Ding et al, 1997). After transfection with
expression plasmid pcDNA/Mdr-1, cells were selected with G418
(GIBCOBRL, 800 µ g ml–1). Individual colonies were isolated
with cloning cylinders to generate cell lines and cell lines
A1847/MDR5 and A1847/MDR3 were used in further study. The
control line (A1847/pcDNA) was generated from cells transfected
with the vector alone and selected using G418. After isolation
of resistant clones, the concentration of G418 was changed to
400 µ gm l –1. 
Western blot analysis 
Cells were harvested by cell lifter and lysed in 0.1 ml lysis buffer
containing 50 mM Tris-HCl (pH 7.6), NaCl (100 mM), EDTA
(2 mM), 1% (v/v) NP40, sodium orthovanadate (1 mM) and phenyl-
methylsulfonyl fluoride (1 mM). Protein samples were sonicated
using an MSE Soniprep (two 5 second bursts at amplitude microns of
12 with sample kept on ice). Proteins samples were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS/PAGE), transferred to a Nitrocellulose membrane and probed
with primary antibody as detailed previously (Ding et al, 1997).
Immunoblots were developed using the enhanced chemilumines-
cence (ECL Plus) Western blotting kit (Amersham). 
MTT assay for cytotoxicity 
Taxol-induced cytotoxicity was determined using the MTT assay
(Mosmann, 1983). Briefly, cells were trypsinised and plated out at
a density of 3000 cells per well into 96 well plates. Cells were
cultured overnight and re-fed with fresh medium with various
concentrations of Taxol (1.0 × 10–9–2.0 × 10–5 M). For the pre-
treatment, cells were treated with PD098059 (30 µ M) or UO126
(20 µ M) for 2 hours. Then cells were treated with various concen-
trations of Taxol plus a fixed concentration of inhibitors. 72 h later
50 µ l of 2 mg ml–1 MTT (3-(4,4-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma, Poole, UK) in PBS were
added to each well, incubated for 4 h at 37˚C and the formazan
crystals formed were dissolved in 50 µ l of DMSO. The optical
density was recorded at 570 nm on a microplate reader (BIO-
RAD). Cytotoxicity is expressed as IC50 for each of the cell lines,
this is the concentration of drug that caused a 50% reduction in the
absorbance at 570 nm relative to untreated cells (control) or cells
treated with inhibitor alone. 
Phosphorylation of MDR-1 
Cells were plated into 6-well culture plates and cultured in RPMI
medium supplemented with 10% fetal calf serum, (100 U ml–1)
penicillin and (100 µ g ml–1) streptomycin (GIBCOBRL, Paisley,
UK) at 37˚C in a 5% CO2 atmosphere overnight. The growth
medium was replaced with PO4-free medium for 1 h, and then
supplemented with 250 µ Ci of 32PO4 per well. After 2 h incubation
at 37˚C, the culture medium was replaced with unlabelled
medium. Cells were treated with PD098059 (30 µ M) or stau-
rosporine (50 nM) for 1 h. Reactions were terminated by lysing the
cells in ice-cold lysis buffer. 32PO4-labelled MDR-1 was immuno-
precipitated by the incubation with anti-Pgp antibody C219 or an
anti-peptide antibody. The results shown are representative of at
least 2 separate observations using either method. 
Transporter assays 
Cells (5 × 105) were seeded into 6-well culture plates and
cultured overnight. The growth medium was replaced with fresh
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Figure 1 Correlation between the degree of Taxol resistance and expression of MDR-1 in parental and Taxol-resistant derivatives of A1847 cells. 
(A) Cytotoxicity of Taxol in parental A1847 cells and in sub-lines growing in the presence of 0.5, 1.0 and 3.0 µ M Taxol respectively. Cell survival was determined
following a 72 hour incubation in the presence of various concentrations of Taxol from 1.0 × 10–9 to 2.0 × 10–5 M using the MTT assay as described in the
Methods. The percentage of viable cells was calculated by dividing the MTT activity of treated cells by those treated with DMSO alone. The results shown are
mean ± SD of at least triplicate wells from 3 independent experiments. (B) Expression of MDR-1 protein in A1847 cells and in Taxol-resistant sublines. MDR-1
expression was analysed by Western blot analysis using 25 µ g of total cellular protein per lane. Proteins were separated on 7.5 % SDS-PAGE gels, transferred
to a nitrocellulose membrane and probed with anti-MDR-1 monoclonal antibody (1/200 dilution) as described in the Methods. (C, D) Cytotoxicity of Taxol and
expression of MDR-1 in transfected cell lines (MDR3 and MDR5) and in control cell line A1847/pcDNA transfected with vector alone. Assays were carried out as
described in A and Bmedium. Cells were pre-treated with DMSO (as control),
PD098059(30 µ M) for 2 h, or with verapmil (25 µ M) for 30 min,
and then supplemented with 1 µ M vinblastine (the ratio of
labelled to unlabelled vinblastine was 100:1, and the specific
activity of 3H-vinblastine was 12.7 Ci mmol–1) for 20 min.
Reactions were terminated by aspirating the radioactive medium,
and cells were washed with PBS 3 times. Cells were lysed in 0.5
ml of 0.4 M NaOH, and then neutralised with 0.5 ml of 0.4 M
ammonium acetate, pH 6.6. Radioactivity was determined in
duplicate in a liquid scintillation counter WALLAC 1409. Cell
number in control wells was counted and results were then
normalised against cell number (1 × 106). 
RESULTS 
Over-expression of MDR-1 in Taxol-resistant sublines
of A1847 
We generated a panel of resistant sub-cell lines of the ovarian
cancer cell line A1847. Cells were exposed to a mutagen
EMS (ethyl methane sulfonate) for 24 h and then selected in
increasing concentrations of Taxol (from 2.5 nM to 10 µ M).
Single colonies were isolated to generate clonal cell lines
which would grow in the presence of, 0.5 µ M (A1847/TX0.5),
1 µ M (A1847/TX1) and 3 µ M (A1847/TX3) Taxol respectively.
These cell lines exhibited very marked increases in Taxol
resistance in cell cytotoxicity assays (Figure 1A). The
degree of the resistance of each line correlated with the final
Taxol concentration to which it had originally been exposed.
The IC50 value for cell line A1847/TX0.5 (8.8 ± 2.9 µ M)
was more than 1000-fold higher than that of the parental cell line
(7.1 ± 2.8 nM). In the case of A1847/TX3, the IC50 could not
be determined because even at the solubility limit of Taxol
(100 µ M) more than 70% of the cells remained viable. 
The multidrug resistance transporter MDR-1 has been associ-
ated with resistance to Taxol (Sandor et al, 1998). We therefore
determined whether the expression of this gene as well as certain
other genes implicated in drug resistance such as glutathione S-
transferase pi (GSTP1) had changed. No change in GSTP1 levels
were seen (data not shown). However, a marked elevation in
MDR-1 protein was observed in the resistant cells as shown
(Figure 1B) which correlated well with the degree of resistance.
Furthermore, Southern blot analysis revealed that the overex-
pression was due to amplification of the Mdr-1 gene (data not
shown). To determine whether the increased expression of MDR-
1 was responsible for the Taxol-resistance, wild-type A1847
cells were stably transfected with the Mdr-1 cDNA to generate
the cell lines A1847/MDR5 and A1847/MDR3 (Figure 1D).
These cells exhibited 300-fold (A1847/MDR5) and 850-fold
(A1847/MDR3) higher Taxol resistance than cells transfected
with vector alone (A1847/pcDNA) (Figure 1C). This resistance
correlated well with the levels of MDR-1 determined by Western
blot analysis. Although this finding together with other published
results (Bosch and Groop, 1996; Sandor et al, 1998) shows the
role of MDR-1 in drug resistance, it was reported recently that
Taxol resistance can develop via either MDR-1-mediated or non-
MDR-1-mediated mechanisms in ovarian and other cancers
(Sarris et al, 1996; Parekh et al, 1997). Therefore, other genes
such as those involved with signal transduction pathways may be
involved. 
Role of cell signalling 
Cell signalling cascades are important in both tumour pathogen-
esis and progression. Antitumour agents are known to activate the
MAP kinase pathways and as a consequence affect tumour cell
drug resistance (Dent et al, 1998). We therefore studied their
expression and activity in the A1847 cell line and its drug resistant
sub-lines. 
Exposure of the parental A1847 cells to Taxol resulted in a tran-
sient activation of ERK1/2, the activation occurring 30 min after
treatment with Taxol, and reaching a maximum at 8 h, declining
thereafter (Figure 2A). In order to characterise the role of these
signalling pathways in Taxol-resistant cell lines immunoblots on
the cell lines were carried out with antibodies against phosphory-
lated ERK1/2. Interestingly, constitutive activation of ERK1/2 was
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Figure 2 Changes in cell signalling pathways in Taxol resistant cells. Total
cell lysates were prepared from cells treated with DMSO alone (–) or cells
treated with specific inhibitors or activators of the pathways being
investigated (+). Protein samples (25 µ g) were run on 10% SDS-PAGE gels
and probed with antibodies either specific to the phosphorylated protein (top
panels) or to the protein in general (A, B and D) allowing both the level of the
protein and its activation state to be determined. (A) Activation of the ERK
1/2 MAP kinase pathway in A1847 cells following exposure to Taxol (1 µ M).
(B) Constitutive activation of ERK1/2 MAP kinase in the Taxol-resistant cell
lines. (+) represents cells treated with PD098059 (30 µ M). (C) JNK activity in
the A1847 cells. The presence of inducible JNK was tested by incubation in
the presence of 0.5 mM sodium arsenite (+). (D) Activity of Akt/PKB in
untreated and treated cells with LY294002 (20 µ M) observed in all the Taxol-resistant cells in the absence of Taxol, but
not in the parental cells. This was completely abrogated by the
MEK1 inhibitor PD098059 (Alessi et al, 1995) (Figure 2B). The
expression and activation of JNK or p38 was also determined. No
constitutive activity was observed in any of the cell lines (Figure
2C), however an inducible JNK activity was shown to be present
in all cell lines following exposure to the known activator of this
pathway, sodium arsenite. 
To determine whether the P13K pathway was activated in
A1847 or A1847/TX0.5 cells, immunoblot analysis using an anti-
body against phospho-Akt/PKB was carried out. This showed
that there was a low level of activity in wild-type cells and the
level of activation was increased in the A1847/TX0.5 cells
(Figure 2D). 
In order to further characterise the role of these pathways in 
the generation of drug resistance, several small molecule chem-
ical inhibitors were tested to determine their effect on the 
Taxol-resistant phenotype. In view of the constitutive activation
of ERK1/2 MAP kinase, we determined whether PD098059
could increase the Taxol sensitivity. PD098059 sensitised both
wild-type (2-fold, P < 0.05) and Taxol-resistant A1847TX0.5
cells (26-fold) (Figure 3A and Table 1). In addition, LY294002,
an inhibitor of the PI3K pathway (Davies et al, 2000) increased
the Taxol sensitivity in the Taxol-resistant A1847/TX0.5 cells
(20-fold) and 1847/MDR5 cells (10-fold), but had no effect on
the wild-type cells (Table 1). Treatment with LY294002 blocked
the phosphorylation of Akt/PKB in the cells. The inhibitor of the
p38 pathway, SB203580 (Davies et al, 2000) did not affect the
Taxol sensitivity in any of the cell lines tested (Figure 3). The
above data suggest that both the ERK1/2 and PI3K, but not the
p38 pathway may play a role in the generation of Taxol resistance
in A1847 cells. 
Evaluation of whether the constitutive activation of
ERK1/2 and PI3K are linked to the over-expression of
MDR-1 
The transient activation of ERK1/2 following Taxol exposure has
been associated with Taxol treatment (Schulte et al, 1996;
Blagosklonny et al, 1999). Therefore, the constitutively elevated
activity in the Taxol-resistant cell lines could be a consequence of
the selection process. There is a report on the constitutive activa-
tion of ERK1/2 in Taxol-resistant breast tumour cells, which was
attributed to the presence of residual Taxol in these MDR-1-
expressing cells (Emanuel et al, 1999). In addition, the elevated
PI3K activity could also contribute to such a selective advantage.
The alternative possibility is that these pathways are metabolically
linked with MDR-1 over-expression. In order to evaluate these
possibilities we measured ERK1/2 and PI3K activities in the cell
lines transfected with Mdr-1 (Figure 4A). Intriguingly, in these
cells, which were not exposed to Taxol, a constitutive activation of
ERK1/2 was also observed. The degree of activation correlated
with the level of MDR-1 expression (Figures 4A and 1D). No acti-
vation in the control cell line A1847/pcDNA was observed.
However, PKB was not activated by MDR-1 overexpression in the
Signalling pathways and MDR-1 1179
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Figure 3 Effect of signalling inhibitors on Taxol toxicity in wild type A1847
and A1847/TX0.5 cells. MTT cytotoxicity assays were carried out as
described in Figure 1A. Cells were pre-treated with PD098059 (30 µ M for 2
hours), LY294002 (20 µ M for one hour), SB203580 (10 µ M for one hour)
respectively. Cells were then continuously exposed to Taxol plus the same
concentration of inhibitors for 3 days before assay for cell survival. The
percentage of viable cells was calculated by dividing the absorbance of cells
treated with inhibitor alone by those treated with Taxol plus inhibitor. The
results shown are mean ± SD of at least triplicate wells from 3 independent
experiments 
Table 1 Effects of signalling inhibitors on Taxol sensitivity 
Cell line Taxol Taxol+PD098059  Taxol+UO126 Taxol+LY294002 
A1847 7.1 ± 2.8 nM 3.5 ± 0.8 nM ND †6.2 ± 0.1 nM 
A1847/TX0.5 8.80 ± 2.90 µ M 0.34  ± 0.02 µ M ND 0.46  ± 0.01 µ M 
A1847/pcDNA 5.8 ± 0.4 nM  2.8 ± 0.1 nM 2.0 ± 0.5 nM  †5.8 ± 0.5 nM 
A1847/Mdr5 2.12 ± 0.61 µ M 0.02  ± 0.01 µ M 0.10  ± 0.01 µ M 0.22  ± 0.01 µ M 
The values shown are IC50 values obtained from MTT assays using the cell lines: A1847 wild type; /TX0.5 Taxol resistant;
/pcDNA3 transfected with vector alone; /Mdr5 transfected with Mdr-1 cDNA and expressing Mdr-1. IC50 values were obtained
in taxol-treated cells or cells treated with taxol plus: PD098059 (30 µ M), UO126 (20 µ M) or LY294002 (20 µ M). Values are
mean ± SD from a minimum of three experiments. †, All data when compared to appropriate control is significant (at least 
P < 0.5) with the exception of (†) where P > 0.5, and not significant.A1847/MDR5 cells (Figure 2D), indicating that the elevated PKB
activity observed in A1847/TX0.5 cells is unrelated to expression
of MDR-1. 
Reversal of Taxol cytotoxicity in MDR-1 transfectants 
We then investigated whether the inhibition of ERK1/2 MAP
kinase pathway would also affect the resistant phenotype of 
the Mdr-1 transfected cells. When A1847/MDR5 cells were
treated with PD098059 (30 µ M) an 88-fold sensitisation to
Taxol cytotoxicity was observed (Figure 4B, Table 1). This
change was paralleled by a complete inhibition of ERK1/2 activity
(Figure 4A). The effects of PD098059 treatment were similar to
the potent inhibitor of MDR-1 protein, verapamil (Tsuruo et al,
1981). Verapamil is a classical inhibitor of MDR-1 and therefore a
positive control in these experiments. To assess whether
PD098059 and verapamil could synergise and enhance the cyto-
toxicity of Taxol the 2 compounds were applied together. This is
not an unreasonable hypothesis if PD098059 and verapamil affect
MDR-1 function by different mechanisms. PD098059 in combina-
tion with verapamil further sensitised the cells to Taxol (2-fold, 
P < 0.05). UO126 (20 µ M), an alternative inhibitor of the ERK 1/2
MAP kinase pathway (Favata et al, 1998), also sensitised the
A1847/MDR5 cells to Taxol (20-fold) (Table 1) and completely
blocked the phosphorylation of ERK1/2 (Figure 4A), supporting
the role of this pathway in Taxol resistance. However, the fact that
U0126 was less efficacious perhaps suggests an additional target
for PD098059? Interestingly, treatment of the A1847/MDR5 cells
with the PI3K inhibitor LY294002 increased Taxol sensitivity
some 10-fold (Table 1), although the level of phospho-Akt
remained unchanged in the cells compared to A1847/pcDNA cells
(Figure 2C). 
Interrelationship between ERK1/2 MAP kinase and
MDR-1 
Phosphorylation 
It is known that MDR-1 is phosphorylated on serine residues 669
and 681 in vivo by the protein kinases PKA and PKC. The
evidence, to date, that phosphorylation of MDR-1 is directly
involved in the regulation of drug transport activity is, however,
contradictory since alterations in the phosphorylation state have
been associated with both enhancement and inhibition of drug
transport (Smith and Zilfou, 1995). Treatment with the protein
kinase inhibitor staurosporine decreases phosphorylation of MDR-
1 and increases drug accumulation (Castro et al, 1999). However,
we found that treatment with this compound had no effects on 
the response of A1847/TX0.5 and A1847/MDR5 cells to Taxol
(data not shown). To further explore the possible role of constitu-
tively activated ERK1/2 in the phosphorylation of MDR-1,
A1847/MDR5 cells were labelled with 32PO4 and then exposed to
PD098059 or staurosporine, respectively, and the MDR-1
immunoprecipitated. No change in the level of phosphorylation of
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Figure 4 Constitutive ERK 1/2 activity in MDR-1 transfected A1847 cells and the effect of inhibition of this pathway on Taxol cytotoxicity. (A) Phospho-ERK1/2
and the overall ERK1/2 levels were determined in the control cell lines (A1847/pcDNA) or cell lines stably transfected and expressing MDR-1 (MDR3 and
MDR5). The analysis was carried out and probed as described in Figure 2 and ‘Materials and Methods’. (B) Effect of ERK 1/2 MAP kinase inhibition on Taxol
cytotoxicity. MTT cytotoxicity assays were carried as described in Figure 3 MDR-1 was observed (Figure 5A) indicating that activation of the
ERK1/2 did not affect this aspect of MDR-1 function. 
Transporter function 
Recently, it has been found that some inhibitors of PKC may block
drug transport by direct competition with the transported drug
rather than by effects on MDR-1 phosphorylation per se (Castro 
et al, 1999). We therefore studied the effects of PD098059 on
drug transporter activity in the A1847/MDR5 cell line, using 
(G-3H)-vinblastine as substrate. Radiolabelled Taxol was, unfortu-
nately, unavailable for these experiments. In the wild-type cells,
neither the MDR-1 reversing agent verapamil nor PD098059 had
significant effect on drug accumulation which is consistent with
the very low MDR-1 levels in these cells (Figure 5B). Drug
accumulation was, however, lower in the A1847/MDR5 cell line
using 3H-vinblastine as a substrate. Although verapamil caused a
marked increase in drug accumulation, PD098059, which was
equipotent in reversing the same degree of drug resistance, only
increased accumulation of 3H-vinblastine by 60% of the appro-
priate control value (Figure 5B). Thus there is a poor correlation
between the reversal of drug accumulation and the resulting
increase in drug sensitivity. Nevertheless, PD098059 treatment
may slightly increase the actual drug concentration in resistant
cells and the reversal of Taxol resistance might partially result
from this effect. In addition, the level of MDR-1 protein was
unchanged upon treatment with PD098059 (not shown).
Collectively, these data indicate that PD098059 is affecting some
other function of the MDR-1, perhaps hitherto not ascribed to this
protein or is acting by an alternative mechanism. 
DISCUSSION 
In this paper we have investigated the ability of a range of
signalling inhibitors to sensitise ovarian cancer cell lines to Taxol.
Interestingly, all the inhibitors tested only reversed drug resistance
significantly in cell lines overexpressing the drug transporter
MDR-1. The effects were particularly marked in cell lines trans-
fected with the Mdr-1 cDNA, indicating that the effects could be
directly ascribed to the overexpression of this protein. The over-
expression of MDR-1 resulted in the activation of the ERK 1 and
ERK 2 pathways. This finding could rationalise the effects
observed with the MAP kinase inhibitors PD098059 and U0126,
as the activity of this pathway in the wild-type cell line was
extremely low. 
We could find little evidence that PD098059 could act as an
MDR-1 antagonist, in the same manner that say verapmil does,
therefore these effects in part could be ascribed to inhibition of the
ERK1/2 pathway. However, there are a variety of mechanisms by
which this could occur. In the first case, the ERK1/2 cascade is
involved in the phosphorylation of a number of proteins, including
transcription factors involved in determining cell survival and
death (Hunter, 1997). PD098059 could therefore reverse changes
in drug resistance mediated by this pathway directly. Alternatively,
there may be direct cross-talk between the ERK1/2 signalling
cascade and MDR-1 function i.e. that activation of the ERK1/2
either directly or indirectly affects the activity of the MDR-1
protein, by changing its phosphorylation state for example.
However, we have been able to find no evidence of altered MDR-
1 phosphorylation in cells grown in the presence of the PD098059
compound. In any event the role of phosphorylation of MDR-1 by
other kinases, such as PKC, in modulating its function has also
recently been called into question (Castro, 1999). It is feasible that
the effects of PD098059 are by some alternative hitherto unknown
mechanism. However, these would still be linked to Mdr-1 expres-
sion. The fact that PD098059 could reverse drug resistance to a
greater extent than the alternative MEK inhibitor U0126 indicates
that there may be an additional targets for this chemical. This is
substantiated by recent evidence that PD098059 can interact with
other cellular targets such as the Ah receptor and inhibit other
signalling cascades such as those mediated by ERK 5 and the
COX1/2 pathways for instance (Borsch-Haubold et al, 1998;
Davies et al, 2000). In addition, Zuber et al (2000) report that in a
genome-wide survey of Ras transformation targets, PD098059
treatment of cells has effects on 61 Ras targetted genes, blocking
down-regulation of 36 genes and up-regulation of 25 targets
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Figure 5 Effect of ERK 1/2 MAP kinase inhibition on MDR-1
phosphorylation and function. (A) MDR-1 phosphorylation was determined by
incubating A1847/MDR5 cells with labelled 32PO4 alone (lane 1), in the
presence of 30 µ M PD098059 for 1 h (lane 2) or in the presence of 100 nM
staurosporine for 1 h (lane 3). Phospho-MDR-1 was immunoprecipitated from
the solubilized cells using the MDR-1 antibody C219. Immunoprecipitates 
(30 µ g) were then analysed on 7% SDS-PAGE and the bands visualised by
autoradiography. Further details are given in the Methods section. (B) Effect
of ERK1/2 inhibition on drug accumulation. Control or A1847/MDR5 cells
were incubated alone or in the presence of PD098059 (30 µ M) or verapamil
(25 µ M) and the accumulation 3H-vinblastine was determined. Measurements
were made 20 min after the substrate addition as described in Materials and
Methods. The results shown are mean ± SD of at least 3 independent
experiments. ** indicates statistical significance (P < 0.05) compared with the
corresponding control including COX 1 and 2. Such changes in gene expression could
have a profound effect upon the sensitivity of cell lines concomit-
tantly exposed to chemotherapeutic agents. We suggest that the
mechanism of action underlying certain of the changes observed in
our own cell lines could be due, in part, to some of these ‘extra-
neous’ effects. 
However, it is important to note that in all our studies to date the
substantive increase in the drug sensitivity using ERK1/2
inhibitors has only been observed in cell lines overexpressing
MDR-1. This indicates that the use of small molecule inhibitors,
such as PD098059, to reverse drug resistance in cancer patients
may be dependent on whether or not this transporter protein is
overexpressed. 
How MDR-1 results in the activation of ERK1/2 is unclear and
may identify novel functions of this protein. Certain of these
possible pathways are outlined in Figure 6. MDR-1, which is
localised at the plasma membrane, may interact directly or indi-
rectly with membrane-bound receptor tyrosine kinases (RTKs)
known to be overexpressed in many tumours (Yao et al, 1988).
Aberrant expression and/or activation of signal transducing
proteins have been linked to various cancers. Over-expression of
the epidermal growth factor receptor tyrosine kinase (c-erb-B1)
gene has been observed in several human cancers including
ovarian and breast (Yao et al, 1988). MDR-1 itself, particularly
when over-expressed, might stimulate the interaction between
these receptors and their effectors causing an activation or even
inhibition of the downstream pathway. Indeed, it has been found
that the expression of MDR-1 can block apoptosis induced by the
Fas ligand cascade (Smyth et al, 1998). Expression of MDR-1
resulted in a decrease in the rate of production of active caspase-
3, a key effector caspase in the apoptotic cascade, upon Fas liga-
tion. Inhibition of MDR-1 function restored caspase 3 activation
upon cross-linking of the cell surface Fas. However, cells retained
their sensitivity to caspase-independent cell death stimuli regard-
less of their MDR-1 expression. It appears from these findings
that the protection afforded by MDR-1 may in part be dependent
upon the mechanism of action of the cell death mediator, such that
it may protect from Taxol cytotoxicity for example but not that
induced by other agents. The ERK1/2 pathway has also been
shown to inhibit caspase-3 activation (Kim et al, 2000), so it is
possible that some form of synergistic action results in enhanced
drug resistance. 
One further possibility is that MDR-1 may have additional
physiological functions. MDR-1 induces novel Na+ and Cl–-
dependent pathways for transmembrane H+ efflux that results in
intracellular alkalisation (Smyth et al, 1999). Apoptosis induced by
chemotherapeutic agents is preceded by intracellular acidification
and the induction of apoptotic events such as DNA laddering can be
inhibited by increasing the intracellular pH in this manner. In a recent
paper, Wittstein et al (2000) demonstrated that inhibition of the ERK
1/2 pathway using PD098059 resulted in re-alkalinisation of vascular
endothelial cells in perfusion experiments. This effect was thought to
be achieved through the effects of ERK upon anion exchange mech-
anisms at the cell surface. Thus alterations in cellular pH may
directly or indirectly provide the stimulus for a variety of signalling
pathways and responses mediated by both MDR and ERK1/2. 
In addition to activation of the ERK1/2 pathway, activated
Akt/PKB a possible mediator of the Taxol-resistant phenotype,
was observed in the 1847/TX0.5 cell line made resistant to Taxol
through media-conditioning. It is well known that PI3Ks play a
central role in cell signalling cascades linked to cell survival. In
mammalian cells there are several forms of PI3K with distinct
functions and multiple downstream effectors including Src
homology-2 (SH2), the PH domain of serine/threonine and tyro-
sine kinases and various cytoskeletal proteins (Franke et al, 1997).
Inhibition of the PI3K, using the inhibitor of PI3K, LY294002,
pathway resulted in a significant sensitisation to Taxol in the drug-
resistant cells. However, no sensitisation was observed in the wild-
type cells. This suggests that the increased PI3K activity could be
linked to the overexpression of MDR-1 in the 1847/TX0.5 drug
resistant cells. However, the activation of Akt/PKB was not
observed in the Mdr-1-transfected cell line, though resistance to
Taxol was reversed using the LY294002 inhibitor. We concluded
from this that PI3K/PKB activation is not a consequence of the
MDR-1 overexpression but is linked to Taxol resistance by
another mechanism. 
Interestingly, Misra et al (1999) have demonstrated that PI3K-
derived lipid products are actually necessary for maximal ATP-
dependent transport across canalicular membrane vesicles.
Inhibition of the pathway using wortmannin or LY294002 blocks
this transport. The effect was not mediated by a direct effect upon
the ATP transporter itself, but rather the inhibition of PI3K activity
and changes mediated through the metabolism of lipid. It is conceiv-
able that the effect observed in the 1847/TX0.5 and 1847/MDR5
cell lines is related to a perturbation in lipid metabolism.
Inhibition of either the PI3K or the p38 pathway alone had
essentially no effect on wild-type cells. Inhibition of ERK1/2
using the PD098059 compound in wild-type cells resulted in
only a 2-fold sensitisation to Taxol. Wild-type cells do not
express detectable levels of MDR-1 and no activation of ERK1/2
is seen. The relative lack of effect is in contrast with reports that
inhibition of these pathways has both a direct and potent anti-
tumour action (Sebolt-Leopold et al, 1999; MacKeigan et al,
2000) and suggests that such effects may well be cell-type
specific or ERK1/2 activation dependent. The generalised use of
such inhibitors as single agents in chemotherapy must therefore
be questionable. In all cell lines transfected with MDR-1,
however, inhibition of the ERK1/2 MAP kinase and PI3K
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Figure 6 Possible interactions between MDR-1 and ERK1/2 MAP kinase.
Overexpression of MDR-1 in the cell membrane may result in several
perturbations of intracellular signalling made evident through activation of the
ERK1/2 MAP kinases pathways by treatments combining Taxol with the appropriate
inhibitors caused a marked (20–88-fold) increase in Taxol
sensitivity. The effect was equivalent to the extensively used
MDR-1 antagonist, verapamil. Furthermore, the combination of
PD098059 with verapamil was synergistic causing a further 2-
fold increase in sensitivity to this drug. 
Collectively these data suggest that such signalling inhibitors
may only be effective in chemotherapy when given in combination
with other drugs and their effectiveness may well depend upon
MDR-1 and ERK1/2 status. 
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